CME restriction bid rebuffed, again

A third attempt by an AMA ethics council asking physicians and medical institutions to curb industry funding for professional educational activities was rebuffed last month.

The proposals, contained in a report from AMA's Council on Ethical and Judicial Affairs (CEJA), would have required CME providers to only accept funds from “sources that have no direct financial interest in a physician's clinical recommendations,” except in certain cases. At the AMA's semi-annual policymaking meeting, its House of Delegates voted to send the entire report back to CEJA for further study.

“The rejection by the House of Delegates shows a commitment to CME funding and academic freedom,” wrote Rockpointe president Thomas Sullivan in the blog Policy and Medicine.

At a committee meeting prior to the vote, 25 speakers representing 24 organizations spoke against adoption of the CEJA recommendations, according to Sullivan, while in favor were 10 speakers representing CEJA, the AMA's Council on Medical Education and other organizations.

The last time delegates sent a CEJA proposal back to committee was in June. That proposal sought to delineate “ethically preferable” or “ethically permissible” CME funding practices. A 2008 proposal—also shelved—had called for an all-out ban on commercial support.

In a statement, AMA chair Dr. Rebecca Patchin said CEJA “will re-examine the issue and present a revised report at a later meeting.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.